InvestorsHub Logo
Followers 5
Posts 475
Boards Moderated 0
Alias Born 09/27/2012

Re: revenue_monster post# 193439

Monday, 10/13/2014 2:50:36 PM

Monday, October 13, 2014 2:50:36 PM

Post# of 346154
There is no publication date in the paper but a footnote references an article in July/Aug 2014 mAbs, so the paper would appear to be very recent.

This study has shown that the PS-targeting antibody, PGN401, binds to EBOV-infected cells and to purified EBOV virions. Due to PGN401 having been used for several human clinical trials in cancer, from Phase I to III [13, 20, 21], its repurposing of use for filovirus therapy through licensure or emergency use may present an attractive option...

Footnotes: 21. Reichert, J.M., Antibodies to watch in 2014: Mid-year update. MAbs, 2014. 6(4): 337 p. 799-802.




How old is this ? Can't find a date

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News